Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Timothy A. Springer net worth and biography

Timothy Springer Biography and Net Worth

Director of Selecta Biosciences

Timothy A. Springer is an entrepreneur who founded 6 companies, including: Morphic Holding, Inc., Scholar Rock Holding Corp. and LeukoSite, Inc. He holds the position of Chairman at Institute For Protein Innovation. He is also Professor at The Children's Hospital Corp., Member of National Academy of Sciences and Professor at Harvard Medical School and on the board of 5 other companies.

In the past Timothy A. Springer was Director at Scholar Rock, Inc. and Independent Director at Scholar Rock Holding Corp.

Dr. Springer received an undergraduate degree from the University of California, Berkeley and a doctorate from Harvard University.

What is Timothy A. Springer's net worth?: The estimated net worth of Timothy A. Springer is at least $0.00 as of February 6th, 2024. Mr. Springer owns 2,933 shares of Selecta Biosciences stock worth more than $0 as of April 26th. This net worth evaluation does not reflect any other assets that Mr. Springer may own. Learn More about Timothy A. Springer's net worth.
How do I contact Timothy A. Springer?: The corporate mailing address for Mr. Springer and other Selecta Biosciences executives is 65 Grove Street, Watertown MA, 02472. Selecta Biosciences can also be reached via phone at (617) 923-1400 and via email at [email protected]. Learn More on Timothy A. Springer's contact information.
Has Timothy A. Springer been buying or selling shares of Selecta Biosciences?: Timothy A. Springer has not been actively trading shares of Selecta Biosciences during the past quarter. Most recently, on Wednesday, December 15th, Timothy A. Springer bought 211,190 shares of Selecta Biosciences stock. The stock was acquired at an average cost of $2.99 per share, with a total value of $631,458.10. Learn More on Timothy A. Springer's trading history.
Who are Selecta Biosciences' active insiders?: Selecta Biosciences' insider roster includes Timothy Barabe (Director), Carsten Brunn (CEO), Nishan de Silva (Director), Timothy Springer (Director), Kevin Tan (CFO), and Peter Traber (Insider). Learn More on Selecta Biosciences' active insiders.
Are insiders buying or selling shares of Selecta Biosciences?: During the last year, insiders at the sold shares 2 times. They sold a total of 3,637 shares worth more than $3,855.22. The most recent insider tranaction occured on September, 25th when CEO Carsten Brunn sold 2,932 shares worth more than $3,107.92. Insiders at Selecta Biosciences own 31.2% of the company. Learn More about insider trades at Selecta Biosciences.
Information on this page was last updated on 9/25/2023.

Timothy A. Springer Insider Trading History at Selecta Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/15/2021	Buy	211,190	$2.99	$631,458.10
12/13/2021	Buy	14,592	$2.98	$43,484.16
12/9/2021	Buy	3,748,000	$3.06	$11,468,880.00
10/22/2020	Buy	1,770,204	$2.63	$4,655,636.52	7,293,625
10/20/2020	Buy	1,887,696	$2.30	$4,341,700.80	7,293,625
10/16/2020	Buy	218,196	$2.42	$528,034.32	7,293,625
10/8/2020	Buy	3,185,394	$1.71	$5,447,023.74	7,293,625
10/6/2020	Buy	2,000,000	$1.68	$3,360,000.00	7,293,625
11/14/2017	Buy	57,598	$9.27	$533,933.46	461,349
6/27/2017	Buy	338,791	$17.71	$5,999,988.61	355,413
6/1/2017	Buy	518	$13.75	$7,122.50	16,622
5/18/2017	Buy	16,104	$14.00	$225,456.00	11,244

Timothy A. Springer Buying and Selling Activity at Selecta Biosciences

Selecta Biosciences Company Overview

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: N/A

50 Day Range

MA: $1.06

$0.88

$1.26

2 Week Range

Now: N/A

Volume

2,774,100 shs

Average Volume

979,585 shs

Market Capitalization

$136.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84